After Another NICE No, Will It Be Third Time Lucky For J&J's Spravato?
Market Access Process For Mental Health Product Proves Challenging
Executive Summary
The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.
You may also be interested in...
US FDA Opens Door For J&J's Spravato To Another MDD Population
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
Sweden’s Egetis Catches The Eye Of Suitors
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
Roche Continues To Cast Its Collaborations Net Wide
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.